1 citations
,
July 2015 in “British Journal of Dermatology” Imiquimod improved skin pigmentation in most patients with xeroderma pigmentosum and may prevent further skin cancer, but some treatments can have side effects.
35 citations
,
January 2006 in “Cancer Research” Mice with extra PKCδ resist chemical-induced skin cancer but not UV-induced.
Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
April 2021 in “Journal of Investigative Dermatology” 7 citations
,
July 2023 in “Immunotherapy” Ritlecitinib works well and is safe for treating alopecia areata.
15 citations
,
September 2014 in “PloS one” The study found that analyzing certain cell signaling pathways is not a reliable method to tell apart two types of skin tumors.
16 citations
,
September 1999 in “Journal of Investigative Dermatology Symposium Proceedings” 665 citations
,
April 2016 in “Nature communications” Blocking specific proteins can help remove aging cells and might treat age-related diseases and promote hair growth.
133 citations
,
May 2016 in “Cell Host & Microbe” Human dermal fibroblasts are the main cells targeted by a virus that can cause a deadly skin cancer, and a certain inhibitor can effectively block this infection.
February 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.
April 2018 in “Journal of Investigative Dermatology” BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.
Deleting Smad4 and PTEN genes in mice causes rapid, invasive stomach cancer.
April 2012 in “Journal of the American Academy of Dermatology” Clofazimine effectively treated ashy dermatosis in a patient.
3 citations
,
August 2024 in “Cureus” Upadacitinib may cause hair loss.
July 2025 in “Pharmaceuticals” Phenobarbital-loaded chitosan nanoparticles are promising for preventing hair loss from chemotherapy.
September 2019 in “Journal of Investigative Dermatology” Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
September 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” EGFR inhibitors cause skin issues and hair loss by weakening skin defenses, suggesting antibiotics and targeted treatments can help.
1 citations
,
November 2024 in “Cureus” Recognizing RSCC is crucial due to its aggressive nature and high risk of poor outcomes.
January 2026 in “Journal of Applied Pharmaceutical Science” Selaginella doederleinii extract shows potential for cervical cancer treatment but needs more research.
2 citations
,
March 2022 in “Modern Rheumatology Case Reports” A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.
10 citations
,
January 2023 in “SAGE Open Medical Case Reports” Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
January 2022 in “Drugs of Today” 6 citations
,
August 2020 in “Oncology nursing forum” Minocycline reduces acne rash, pyridoxine lowers hand-foot syndrome risk, and scalp cooling lessens hair loss from cancer treatments.
1 citations
,
November 2023 in “SKIN The Journal of Cutaneous Medicine”
February 2026 in “Dermatology and Therapy” Sonidegib is effective and safe for treating advanced basal cell carcinoma, but biopsies are needed to confirm tumor clearance.
22 citations
,
March 2017 in “Journal of the Formosan Medical Association” The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.
18 citations
,
February 2023 in “PLoS ONE” A new triple drug system using nanoparticles effectively targets breast tumors in 3D models.